Bright light therapy for improving symptoms in Parkinson's disease
Light Therapy in Parkinson's Disease: a Prospective, Observational Study
This study is testing if bright light therapy can help improve mood, anxiety, and motor symptoms in people with Parkinson's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital of Soochow University Academic / other |
| Locations | 1 site (Suzhou, Jiangsu) |
| Trial ID | NCT06129942 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial aims to investigate the effects of bright light therapy on motor symptoms and sleep disorders in patients with Parkinson's disease. The study involves administering bright light exposure of 4000 to 6000 lux for 60 minutes before bedtime to assess improvements in mood, anxiety, and motor function. Previous open studies have shown promising results, but this trial seeks to confirm these findings specifically in Chinese patients with Parkinson's disease. The research will also explore the underlying mechanisms of how light therapy may benefit these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Parkinson's disease who are in Hoehn and Yahr stages 2-3 and have stable medication regimens.
Not a fit: Patients with significant cognitive impairment, visual impairments, or those using certain medications that affect sleep may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly improve the quality of life for patients with Parkinson's disease by alleviating motor and sleep-related symptoms.
How similar studies have performed: Previous studies have shown success with light therapy in improving symptoms in Parkinson's disease, but this specific approach in Chinese patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * According to the criteria of PD diagnosis of the MDS, PD patients were selected as the research object. The clinical symptoms of PD patients were consistent with Hoehn and Yahr stages 2-3. * All PD patients have maintained stable drug treatment for at least one month, signed clinical informed consent and agreed not to adjust drugs throughout the light test and follow-up period. Exclusion Criteria: * Using hypnotic or stimulating drugs. * Using antidepressants, except stable drugs maintained for more than three months; * Visual impairment, such as cataract, glaucoma, blindness, etc; * Cognitive impairment (MMSE \< 24); * There are uncontrollable hallucinations and mental diseases; * There are sleep phase delay / advance syndrome, shift work, jet lag, etc
Where this trial is running
Suzhou, Jiangsu
- Department of Neurology, Second Affiliated Hospital of Soochow University — Suzhou, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Chun-Feng Liu, PhD — Second Affiliated Hospital of Soochow University
- Study coordinator: Chun-Feng Liu, PhD
- Email: liuchunfeng@suda.edu.cn
- Phone: +86 512 67783307
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.